192 results on '"Laus, G."'
Search Results
2. MCLA-129, a human anti-EGFR and anti-c-MET bispecific antibody, in patients with advanced NSCLC and other solid tumors: an ongoing phase 1/2 study
3. Sex related immunophenothype differences in human stromal vascular fraction from lipospirate and microfragmented lipospirate revealed by polychromatic flow cytometry
4. P76.72 A PET and MRI Study Exploring Osimertinib Brain Exposure and Efficacy in EGFRm NSCLC CNS Metastases
5. Ionic liquids as advantageous solvents for headspace gas chromatography of compounds with low vapor pressure
6. Synthesis of Potent and Enzymatically Stable 4–18F-Benzoyl-NT(8–13) Analogs for Tumour Diagnosis Using PET
7. Frequenz von EGFR (epidermaler Wachstumsfaktorrezeptor)-Mutationen im Stadium IB-IIIA NSCLC nach kompletter Tumorresektion
8. Overall survival (OS) from the AURA3 phase III study: Osimertinib vs platinum-pemetrexed (plt-pem) in patients (pts) with EGFR T790M advanced non-small cell lung cancer (NSCLC) and progression on a prior EGFR-tyrosine kinase inhibitor (TKI)
9. Frequency of epidermal growth factor receptor (EGFR) mutations in stage IB–IIIA EGFR mutation positive non-small cell lung cancer (NSCLC) after complete tumour resection
10. P2.14-33 An Open-Label PET-MRI Study to Determine Brain Exposure of Osimertinib in Patients with EGFR Mutant NSCLC and CNS Metastases
11. Enantiomeric separation of unusual secondary aromatic amino acids
12. 341 (PB121) - MCLA-129, a human anti-EGFR and anti-c-MET bispecific antibody, in patients with advanced NSCLC and other solid tumors: an ongoing phase 1/2 study
13. Inhibition of NF-κB activation by the histone deacetylase inhibitor 4-Me2N-BAVAH induces an early G1 cell cycle arrest in primary hepatocytes
14. Sequence-dependent antiproliferative effects of cytotoxic drugs and epidermal growth factor receptor inhibitors
15. Crystal structure of (E)-2-ruthenocenylethenylcobaltocenium hexafluorophosphate, [(C5H5)Ru(C12H10)Co(C5H5)] [PF6]
16. Crystal structure of sodium 4-azido-1,2,3-triazolide monohydrate, Na(N3C2HN3) · H2O
17. Crystal structure of bis(1-butyl-3-methylimidazolium) hexachlorotitanate( IV) bis(dichloromethane) solvate, (C8H15N2)2[TiCl6] · 2CH2Cl2
18. Crystal structure of iodoferrocene, Fe(C5H4I)(C5H5)
19. Crystal structure of 17-(cyclopropylmethyl)-6,7-didehydro-4,5a-epoxy-3- hydroxy-14β-(3-phenylpropyloxy)indolo[2,3:6,7]morphinan hydroiodide, (C35H37N2O3)I
20. Crystal structure of bis( 1 -butyl-3-methylimidazolium) hexachlorotitanate( IV) bis(dichloromethane) solvate, (C8H15N2)2[TiCl6] · 2CH2Cl2
21. Crystal structure of 5,6-didehydro-14-hydroxy-3-methoxy-17-methy1-4- (trifluoromethylsulfonyIoxy)morphinan-6-carbonitrile, C20H21F3N2O5S
22. Conformationally restricted new somatostatin analogs
23. Analysis of resistance mechanisms to osimertinib in patients with EGFR T790M advanced NSCLC from the AURA3 study
24. Phase-out-compliant fluorosurfactants
25. Dietary restraint, life satisfaction and self-discrepancy by gender in university students
26. Overall survival (OS) in patients (pts) with EGFR T790M-positive advanced non-small cell lung cancer (NSCLC) treated with osimertinib: Results from two phase II studies
27. 475O - Overall survival (OS) from the AURA3 phase III study: Osimertinib vs platinum-pemetrexed (plt-pem) in patients (pts) with EGFR T790M advanced non-small cell lung cancer (NSCLC) and progression on a prior EGFR-tyrosine kinase inhibitor (TKI)
28. 1450P - Frequency of epidermal growth factor receptor (EGFR) mutations in stage IB–IIIA EGFR mutation positive non-small cell lung cancer (NSCLC) after complete tumour resection
29. Phase-out-compliant fluorosurfactants: unique methimazolium derivatives including room temperature ionic liquids
30. Proceedings of the XXII National Conference of the Italian Society of Cytometry GIC, October 4–8, 2005, San Bendetto del Tronto (AP), Italy
31. Sequence-dependent, synergistic antiproliferative and proapoptotic effects of the combination of cytotoxic drugs and enzastaurin, a protein kinase Cbeta inhibitor, in non-small cell lung cancer cells
32. LBA51 - Analysis of resistance mechanisms to osimertinib in patients with EGFR T790M advanced NSCLC from the AURA3 study
33. PARP-1 involvement in growth inhibitory effects of temozolomide and topotecan in wild-type (D54) and p53 mutated (U-251) glioblastoma cells. Intern. Med. J. Exp.Clin. Res
34. 1348P - Overall survival (OS) in patients (pts) with EGFR T790M-positive advanced non-small cell lung cancer (NSCLC) treated with osimertinib: Results from two phase II studies
35. Synergistic antitumor activity of the combination of the multi-targetes tyrosine kinase inhibitor sorafenib and of EGFR inhibitors in human colon and lung cancer cell lines
36. Potentiation of the antitumor acitivity of bortezomib, a proteasome inhibitor, by the combination with EGFR inhibitors in human cancer cell lines
37. The farnesyltransferase inhibitor R115777 (Zanestra) synergizes with ionizing radiation in inducing cell cycle perturbation and growth inhibition of human epidermoid head and neck cancer cells
38. Inhibition of NF-kB activity potentiates ionizing radiation and cisplatin induced cell killing of anaplastic thyroid carcinoma cells AACR Meeting Abstracts, Apr 2006; 2006: 1038
39. SIMO and MIMO PHIL Methods for Distributed Generation in LV Networks
40. Synthesis of Substituted Benzoxazolinones by the Curtius Rearrangement: Crystal Structures of Intermediates and By-Products
41. Inhibition of NF-κB activation by the histone deacetylase inhibitor 4-Me2N-BAVAH induces an early G1cell cycle arrest in primary hepatocytes
42. Inhibition of NF-?B activation by the histone deacetylase inhibitor 4-Me2N-BAVAH induces an early G1cell cycle arrest in primary hepatocytes
43. A Metabolic Screening Study of Trichostatin A (TSA) and TSA-Like Histone Deacetylase Inhibitors in Rat and Human Primary Hepatocyte Cultures
44. 399 POSTER Synergistic antitumor activity of the combination of the multi-targeted tyrosine kinase inhibitor sorafenib and of EGFR inhibitors in human colon and lung cancer cell lines
45. 397 POSTER Potentiation of the antitumor activity of bortezomib, a proteasome inhibitor, by the combination with EGFR inhibitors in human cancer cell lines
46. Role of metalloproteinase-7 in oxaliplatin acquired resistance in colorectal cancer cell lines
47. Lattice Architecture and Hydrogen-Bonding Networks of N-Aminoazolium and N,N‘-Diaminoazolium Chlorides
48. Electrochemical bromination of cholest-5-enes
49. Ionic Liquids as Advantageous Solvents for Headspace Gas Chromatography of Compounds with Low Vapor Pressure
50. Poly(ADP-ribose)polymerase (PARP-1) expression in malignant melanomas from photo exposed areas of the head and neck region
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.